Effects of octreotide on liver metastasis and intrametastatic lipid peroxidation in experimental pancreatic cancer.
OBJECTIVE
In prospective clinical trials, octreotide improved the quality of life and survival time in patients with pancreatic cancer. In this study, we analyzed whether octreotide modulates the intrametastatic oxygen radical metabolism and might decrease liver metastasis in a model of pancreatic cancer.


METHODS
Syrian hamsters received 0.9% NaCl or N-nitrosobis(2-oxopropyl)amine for 3 months. Therapy was performed for 12 weeks by 0.9% NaCl or octreotide. Hamsters received a standard diet or were fed a high-fat diet. In the 25th week, pancreas and liver were examined macroscopically and histologically. The level of lipid peroxidation and the activity of glutathione peroxidase and superoxide dismutase were determined intrahepatically and intrametastatically.


RESULTS
The number and size of liver metastases per animal were increased by high-fat diet and decreased by octreotide. While high-fat diet increased intrahepatic extrametastatic lipid peroxidation, octreotide decreased intrahepatic extrametastatic lipid peroxidation and increased intrametastatic lipid peroxidation.


CONCLUSIONS
Octreotide decreases the number and size of liver metastases in chemically induced pancreatic cancer in Syrian hamsters. Possible mechanisms are the prevention of high lipid peroxidation in non-metastatic liver as well as the increase in intrametastatic lipid peroxidation, leading to loss of integrity of spread tumor cells.
Wenger
F A
FA
Department of General, Visceral, Vascular and Thoracic Surgery, Charité Campus Mitte, Humboldt University of Berlin, Germany.
Kilian
M
M
Jacobi
C A
CA
Mautsch
I
I
Peter
F J
FJ
Guski
H
H
Schimke
I
I
Müller
J M
JM
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006224:Cricetinae; D005979:Glutathione Peroxidase / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects*; D008114:Liver Neoplasms, Experimental / Q000378:metabolism*; D008297:Male; D008647:Mesocricetus; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013482:Superoxide Dismutase / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D015282:Octreotide